search
Back to results

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

Primary Purpose

Obesity

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tadalafil 20 MG
Placebo
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

19 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults
  • Obesity (BMI ≥ 30 kg/m2)

Exclusion Criteria:

  • Age <19 or > 50
  • BMI < 30 kg/m2
  • Systolic blood pressure (SBP) < 100, > 150 mmHg
  • Current anti-hypertensive medication use, including diuretics
  • Current use of organic nitrates
  • Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)
  • History of reaction to PDE-5 inhibitors
  • Known HIV infection
  • Use of medications that strongly alter CYP3A4 activity
  • History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, or seizure
  • Known non-arteritic ischemic optic retinopathy (NAIOR)
  • History of hearing loss
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation
  • Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of normal
  • Known pregnancy or breastfeeding or those unwilling to avoid pregnancy during the course of the study
  • History of priapism
  • Use in excess of four alcoholic drinks daily
  • History of diabetes mellitus or use of anti-diabetic medications
  • Known anemia (men, Hct < 38% and women, Hct <36%)
  • Menopause
  • Weight > 300 pounds
  • Individuals with circadian rhythm disorders, shift workers, or those who travel across time zones frequently

Sites / Locations

  • Vanderbilt University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Tadalafil

Placebo

Arm Description

Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.

Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.

Outcomes

Primary Outcome Measures

Thermoneutral FSF of WAT at the level of the umbilicus at 12 Weeks.
MRI measurement of lipid content
Subcutaneous adipose tissue expression of UCP1 (normalized expression units)
Measurement of gene expression in adipose sample

Secondary Outcome Measures

Thermoneutral fat signal fraction of brown adipose tissue
MRI measurement of lipid content
Cold-exposed fat signal fraction of white adipose tissue and grown adipose tissue
MRI measurement of lipid content
Subcutaneous adipose tissue gene expression of mitochondrial genes (normalized expression units)
Measurement of gene expression in adipose sample
Subcutaneous adipose tissue natriuretic peptide receptor expression
Measurement of gene expression in adipose sample

Full Information

First Posted
December 16, 2020
Last Updated
April 6, 2023
Sponsor
Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04684589
Brief Title
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
Official Title
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 16, 2021 (Actual)
Primary Completion Date
July 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene expression.
Detailed Description
The purpose of this study is to test whether tadalafil causes subcutaneous adipose tissue to have a "beige" phenotype. Participants will be randomized to either placebo or tadalafil for 12 weeks. Investigators will study adipose metabolism using MRI scans and aspiration of subcutaneous adipose from the abdomen. In addition to MRI scans at room temperature, the investigators will use a cooling protocol to test the combined effects of tadalafil and on adipose metabolism. Investigators will also measure the effects of the drug on body composition. In addition to the study visits, participants will wear an activity tracker (Fitbit) and log their dietary intake several times using an online tool. There will be a small amount of radiation exposure. Participants will be compensated for participation in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Half of participants to get tadalafil and half to get placebo.
Masking
ParticipantInvestigator
Masking Description
Double blinded
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tadalafil
Arm Type
Active Comparator
Arm Description
Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
Intervention Type
Drug
Intervention Name(s)
Tadalafil 20 MG
Other Intervention Name(s)
CIALIS
Intervention Description
Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Primary Outcome Measure Information:
Title
Thermoneutral FSF of WAT at the level of the umbilicus at 12 Weeks.
Description
MRI measurement of lipid content
Time Frame
12 weeks
Title
Subcutaneous adipose tissue expression of UCP1 (normalized expression units)
Description
Measurement of gene expression in adipose sample
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Thermoneutral fat signal fraction of brown adipose tissue
Description
MRI measurement of lipid content
Time Frame
Baseline to 12 weeks
Title
Cold-exposed fat signal fraction of white adipose tissue and grown adipose tissue
Description
MRI measurement of lipid content
Time Frame
Baseline to 12 weeks
Title
Subcutaneous adipose tissue gene expression of mitochondrial genes (normalized expression units)
Description
Measurement of gene expression in adipose sample
Time Frame
Baseline to 12 weeks
Title
Subcutaneous adipose tissue natriuretic peptide receptor expression
Description
Measurement of gene expression in adipose sample
Time Frame
Baseline to 12 weeks
Other Pre-specified Outcome Measures:
Title
BAT perfusion under thermoneutral and cold conditions
Description
MRI measurement of blood flow
Time Frame
Baseline to 12 weeks
Title
Change in BNP concentration during cold exposure
Description
Blood measurement of hormone
Time Frame
Baseline to 12 weeks
Title
Change in free fatty acid level during cold exposure
Description
Blood measurement of fat
Time Frame
Baseline to 12 weeks
Title
Change in whole body subcutaneous and visceral fat mass
Description
Measurement of fat mass will be examined using dual x-ray absorptiometry to assess for changes in fat mass.
Time Frame
Baseline to 12 weeks
Title
Resting energy expenditure
Description
Measurement of energy expended
Time Frame
Baseline to 12 Weeks
Title
Homeostatic Index of Insulin Resistance
Description
Blood measurement of insulin resistance
Time Frame
Baseline to 12 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults Obesity (BMI ≥ 30 kg/m2) Exclusion Criteria: Age <19 or > 50 BMI < 30 kg/m2 Systolic blood pressure (SBP) < 100, > 150 mmHg Current anti-hypertensive medication use, including diuretics Current use of organic nitrates Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) History of reaction to PDE-5 inhibitors Known HIV infection Use of medications that strongly alter CYP3A4 activity History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, or seizure Known non-arteritic ischemic optic retinopathy (NAIOR) History of hearing loss Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of normal Known pregnancy or breastfeeding or those unwilling to avoid pregnancy during the course of the study History of priapism Use in excess of four alcoholic drinks daily History of diabetes mellitus or use of anti-diabetic medications Known anemia (men, Hct < 38% and women, Hct <36%) Menopause Weight > 300 pounds Individuals with circadian rhythm disorders, shift workers, or those who travel across time zones frequently
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rashundra Oggs, NP
Phone
615-875-7975
Email
rashundra.n.oggs@vumc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Evan Brittain, MD, MSci
Phone
615-322-4382
Email
Evan.brittain@vumc.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evan Brittain, MD, MSci
Organizational Affiliation
VUMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

We'll reach out to this number within 24 hrs